文献速递白血病MDS 与骨髓增殖性肿瘤

KIT D816突变/CBF阴性急性髓系白血病:与系统性肥大细胞增多症相关的低危亚型

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
PubMed 文献 · Leukemia · 2019-01-11

本研究评估了KIT D816突变/CBF阴性急性髓系白血病的临床与分子特征,所有40例均伴组织学证实的系统性肥大细胞增多症(SM-AML)。中位总生存期5.4个月,32/32例可分析患者至少携带一个额外体细胞突变,提示该亚型预后不良,骨髓组织学与重新分类对预后及治疗选择有重要临床意义。

要点

  • KIT D816突变/CBF阴性AML均伴系统性肥大细胞增多症,中位OS仅5.4个月
  • 所有可分析患者均检出至少一个额外体细胞突变(中位3个),常见SRSF2、ASXL1、RUNX1
  • 独立AML数据库中KIT D816突变/CBF阴性病例与SM-AML特征高度相似,提示部分患者潜在SM

核心结论

  • KIT D816突变/CBF阴性AML是一个与系统性肥大细胞增多症相关的预后不良亚型,骨髓组织学检查和重新分类为SM-AML对预后判断及将KIT抑制剂纳入治疗策略具有重要临床意义。

研究设计与样本

  • 研究纳入40例KIT D816突变/CBF阴性AML患者,所有病例均经组织学证实伴系统性肥大细胞增多症(SM-AML),并进行了临床和分子特征分析;另筛选两个独立AML数据库(n=69)进行对比。

主要发现

  • 所有40例KIT D816突变/CBF阴性病例均有组织学证实的SM伴相关AML(SM-AML)。
  • 32/32例(100%)可分析患者除KIT D816外至少携带一个额外体细胞突变(中位3个),常见SRSF2(38%)、ASXL1(31%)、RUNX1(34%)。
  • 29/40例(73%)患者继发性AML由SM±相关髓系肿瘤演变而来。
  • 15/16例(94%)患者在SM-AML发生时纵向分子和细胞遗传学分析显示获得新突变和/或核型演变。
  • 中位总生存期(OS)为5.4个月。

关键数值与推荐

  • KIT D816突变/CBF阴性SM-AML与KIT D816突变/CBF阴性AML数据库病例(n=69)在KIT D816突变等位基因频率、突变谱、异常核型和OS方面高度相似。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KIT D816 mutations (KIT D816mut) are strongly associated with systemic mastocytosis (SM) but are also detectable in acute myeloid leukemia (AML), where they represent an adverse prognostic factor in combination with core binding factor (CBF) fusion genes. Here, we evaluated the clinical and molecular features of KIT D816mut/CBF-negative (CBFneg) AML, a previously uncharacterized combination. All KIT D816mut/CBFneg cases (n = 40) had histologically proven SM with associated AML (SM-AML). Molecular analyses revealed at least one additional somatic mutation (median, n = 3) beside KIT D816 (e.g., SRSF2, 38%; ASXL1, 31%; RUNX1, 34%) in 32/32 (100%) patients. Secondary AML evolved in 29/40 (73%) patients from SM ± associated myeloid neoplasm. Longitudinal molecular and cytogenetic analyses revealed the acquisition of new mutations and/or karyotype evolution in 15/16 (94%) patients at the time of SM-AML. Median overall survival (OS) was 5.4 months. A screen of two independent AML databases (AMLdatabases) revealed remarkable similarities between KIT D816mut/CBFneg SM-AML and KIT D816mut/CBFneg AMLdatabases (n = 69) with regard to KIT D816mut variant allele frequency, mutation profile, aberrant karyotype, and OS suggesting underlying SM in a significant proportion of AMLdatabases patients. Bone marrow histology and reclassification as SM-AML has important clinical implications regarding prognosis and potential inclusion of KIT inhibitors in treatment concepts.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jawhar M, Döhner K, Kreil S, et al. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019. PMID: 30635631. doi:10.1038/s41375-018-0346-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。